We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Indication Dosage form Strength
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 1, 3 and 6 mg
Rivaroxaban Thrombosis, stroke Film-coated tablets 10, 15 and 20 mg
Rizatriptan Migraine Orodispersable tablets 5 and 10 mg
Rotigotine Parkinson disease & restless legs Patches 1, 2, 3, 4, 6 and 8 mg/24h
Seripnol® Useful to promote relaxation and sleep Mar 2012
Seripnol® drops Useful to promote relaxation and sleep Apr 2014

Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Solifenacin Overactive bladder, urinary incontinence Film-coated tablets 5 and 10 mg
Sulpiride Psychosis, schizophrenia Tablets 50 and 200 mg
Sultiame * Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
Telmisartan Hypertension Tablets 20, 40 and 80 mg
Tolcapone Parkinson's Film-coated tablets 100 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Trazodone Depression XR tablets 75 and 150 mg
Triadenor® Useful for the management of depressive disorders Nov 2014
Trimipramine Depression Oral drops, solution 40mg / ml
UMP + Folic Acid + B12 Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies Jul 2018
Valproate Epilepsy Oral solution 300mg/ ml (100ml)
300mg/ 5ml (250ml)
Valsartan Hypertension Film-coated tablets 40, 80, 160 and 320 mg

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.